InvestorsHub Logo
Post# of 4973165
Next 10
Followers 5
Posts 2568
Boards Moderated 0
Alias Born 11/03/2019

Re: None

Wednesday, 06/01/2022 10:04:41 AM

Wednesday, June 01, 2022 10:04:41 AM

Post# of 4973165
$ATRX Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. $PFE Pfizer 3-dose COVID vaccine 80% effective against symptomatic omicron infection for youngest children.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.